These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 29119445)

  • 21. Exploratory clinical trials: implementation modes & guidelines, scope and regulatory framework.
    Francillon A; Pickering G; Belorgey C
    Therapie; 2009; 64(3):149-59. PubMed ID: 19671427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prospect for bacteriophage therapy in Western medicine.
    Merril CR; Scholl D; Adhya SL
    Nat Rev Drug Discov; 2003 Jun; 2(6):489-97. PubMed ID: 12776223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The regulatory framework for complementary and alternative medicines in Europe].
    Knöss W; Stolte F; Reh K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):771-8. PubMed ID: 18584103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
    Kroes BH
    J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The next generation of bacteriophage therapy.
    Lu TK; Koeris MS
    Curr Opin Microbiol; 2011 Oct; 14(5):524-31. PubMed ID: 21868281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. European regulatory conundrum of phage therapy.
    Verbeken G; De Vos D; Vaneechoutte M; Merabishvili M; Zizi M; Pirnay JP
    Future Microbiol; 2007 Oct; 2(5):485-91. PubMed ID: 17927471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bacteriophages as potential new therapeutics to replace or supplement antibiotics.
    Kutateladze M; Adamia R
    Trends Biotechnol; 2010 Dec; 28(12):591-5. PubMed ID: 20810181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current concepts and future approaches to the development of autologous/autogenous vaccines for veterinary use.
    Tollis M
    Dev Biol (Basel); 2004; 117():55-60. PubMed ID: 15597617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined guide to NRC compliance now available.
    J Nucl Med; 2004 Jun; 45(6):28N. PubMed ID: 15181116
    [No Abstract]   [Full Text] [Related]  

  • 30. The regulatory system in europe with special emphasis on allergen products.
    Lorenz AR; Luttkopf D; Seitz R; Vieths S
    Int Arch Allergy Immunol; 2008; 147(4):263-75. PubMed ID: 18648190
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibacterial bioagents based on principles of bacteriophage biology: an overview.
    Knoll BM; Mylonakis E
    Clin Infect Dis; 2014 Feb; 58(4):528-34. PubMed ID: 24270166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulatory pathways for vaccines for developing countries.
    Milstien J; Belgharbi L
    Bull World Health Organ; 2004 Feb; 82(2):128-33. PubMed ID: 15042235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New governance: can user-promulgated certification schemes provide safer, higher quality food?
    Hass TK
    Food Drug Law J; 2013; 68(1):77-95, ii. PubMed ID: 24640638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Strategy of Voluntary Certification in Italian Olive Oil Industry: Who and Why?
    Riganelli C; Marchini A
    Recent Pat Food Nutr Agric; 2016; 8(1):9-18. PubMed ID: 26957464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The certification of advanced therapy medicinal products. A quality label for product development in small and medium-sized enterprises].
    Berger A; Schüle S; Flory E
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):816-21. PubMed ID: 21698534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role and activities of the ISCT Regulatory Affairs Committee.
    Kelley L
    Cytotherapy; 2003; 5(4):279-83. PubMed ID: 12944232
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phage approved in food, why not as a therapeutic?
    Sarhan WA; Azzazy HM
    Expert Rev Anti Infect Ther; 2015 Jan; 13(1):91-101. PubMed ID: 25488141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of the risk-based, phased-in approach for the international harmonization of the regulation of container closure systems for drugs in Taiwan.
    Chang LC; Kang JJ; Gau CS
    Regul Toxicol Pharmacol; 2016 Jun; 77():252-6. PubMed ID: 27016398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nano/Micro Formulations for Bacteriophage Delivery.
    Cortés P; Cano-Sarabia M; Colom J; Otero J; Maspoch D; Llagostera M
    Methods Mol Biol; 2018; 1693():271-283. PubMed ID: 29119446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bacteriophages as anti-infective agents: recent developments and regulatory challenges.
    Gilmore BF
    Expert Rev Anti Infect Ther; 2012 May; 10(5):533-5. PubMed ID: 22702317
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.